News Release


MSD K.K. receives manufacturing and marketing approval of LYFNUA® Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough

January 20, 2022

Get Adobe Acrobat Reader

Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.

Get Adobe Acrobat Reader